Emerging fungal diseases: The importance of the host

Clinics in Laboratory Medicine

Volumn 24, Issue 3, 2004, Pages 691-719

  Procop, Gary W ^a   Roberts, Glenn D ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ACREMONIUM; ASPERGILLUS; CANCER; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CRITICAL ILLNESS; CRYPTOCOCCUS NEOFORMANS; DEVICE INFECTION; FUNGAL STRAIN; FUNGAL VIRULENCE; FUSARIUM; GRAFT VERSUS HOST REACTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INDWELLING CATHETER; INFECTION RISK; MALASSEZIA; MOULD; MYCOSIS; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PAECILOMYCES; PATHOGENESIS; PENICILLIUM MARNEFFEI; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; REVIEW; RHODOTORULA; SCOPULARIOPSIS BREVICAULIS; STEM CELL TRANSPLANTATION; TRICHOSPORON; YEAST; ZYGOMYCETES;

COMMUNICABLE DISEASES, EMERGING; HUMANS; MYCOSES;

EID: 8444245482     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.05.004     Document Type: Review

References (253)

1. Morse S. Factors in the emergence of infectious diseases. Emerg Infect Dis. 7:1996;7-15
2. Lederberg J., Shope R., Oaks S. Emerging infections: microbial threats to health in the United States. 1992;National Academy Press, Washington, DC
3. Yehia M., Thomas M., Pilmore H., Van Der Merwe W., Dittmer I. Subcutaneous black fungus (phaeohyphomycosis) infection in renal transplant recipients: three cases. Transplantation. 77:(1):2004;140-142
4. Fica A., Diaz M.C., Luppi M., Olivares R., Saez L., Baboor M., Vasquez P. Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana. Scand J Infect Dis. 35:(11-2):2003;892-893
5. Willinger B., Kopetzky G., Harm F., Apfalter P., Makristathis A., Berer A., et al. Disseminated infection with Nattrassia mangiferae in an immunosuppressed patient. J Clin Microbiol. 42:(1):2004;478-480
6. Kaliamurthy J., Kalavathy C.M., Ramalingam M.D., Prasanth D.A., Jesudasan C.A., Thomas P.A. Keratitis due to a coelomycetous fungus: case reports and review of the literature. Cornea. 23:(1):2004;3-12
7. Wang T.K., Chiu W., Chim S., Chan T.M., Wong S.S., Ho P.L. Disseminated ochroconis gallopavum infection in a renal transplant recipient: the first reported case and a review of the literature. Clin Nephrol. 60:(6):2003;415-423
8. Teixeira A.B., Trabasso P., Moretti-Branchini M.L., Aoki F.H., Vigorito A.C., Miyaji M., et al. Phaeohyphomycosis caused by Chaetomium globosum in an allogeneic bone marrow transplant recipient. Mycopathologia. 156:(4):2003;309-312
9. Madariaga M.G., Tenorio A., Proia L. Trichosporon inkin peritonitis treated with caspofungin. J Clin Microbiol. 41:(12):2003;5827-5829
10. Rajendran C., Khaitan B.K., Mittal R., Ramam M., Bhardwaj M., Datta K.K. Phaeohyphomycosis caused by Exophiala spinifera in India. Med Mycol. 41:(5):2003;437-441
11. Horre R., Jovanic B., Marklein G., Schumacher G., Friedrichs N., Neuhaus T., et al. Fatal pulmonary scedosporiosis. Mycoses. 46:(9-10):2003;418-421
12. Swoboda-Kopec E., Wroblewska M.M., Rokosz A., Luczak M. Mixed bloodstream infection with Staphylococcus aureus and Penicillium chrysogenum in an immunocompromised patient: case report and review of the literature. Clin Microbiol Infect. 9:(11):2003;1116-1117
13. Marty F.M., Barouch D.H., Coakley E.P., Baden L.R. Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol. 41:(11):2003;5317-5320
14. Nir-Paz R., Elinav H., Pierard G.E., Walker D., Maly A., Shapiro M., et al. Deep infection by Trichophyton rubrum in an immunocompromised patient. J Clin Microbiol. 41:(11):2003;5298-5301
15. Gan G.G., Kamarulzaman A., Goh K.Y., Ng K.P., Na S.L., Soo-Hoo T.S. Non-sporulating Chrysosporium: an opportunistic fungal infection in a neutropenic patient. Med J Malaysia. 57:(1):2002;118-122
16. Carey J., D'Amico R., Sutton D.A., Rinaldi M.G. Paecilomyces lilacinus vaginitis in an immunocompetent patient. Emerg Infect Dis. 9:(9):2003;1155-1158
17. Nobrega J.P., Rosemberg S., Adami A.M., Heins-Vaccari E.M., Lacaz Cda S., de Brito T. Fonsecaea pedrosoi cerebral phaeohyphomycosis (" chromoblastomycosis"): first human culture-proven case reported in Brazil. Rev Inst Med Trop São Paulo. 45:(4):2003;217-220
18. Bolignano G., Criseo G. Disseminated nosocomial fungal infection by Aureobasidium pullulans var. melanigenum: a case report. J Clin Microbiol. 41:(9):2003;4483-4485
19. Greig J., Harkness M., Taylor P., Hashmi C., Liang S., Kwan J. Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis. Clin Microbiol Infect. 9:(7):2003;713-715
20. Shenoy R., Shenoy U.A., al Mahrooqui Z.H. Keratomycosis due to Trichophyton mentagrophytes. Mycoses. 46:(3-4):2003;157-158
21. Murayama N., Takimoto R., Kawai M., Hiruma M., Takamori K., Nishimura K. A case of subcutaneous phaeohyphomycotic cyst due to Exophiala jeanselmei complicated with systemic lupus erythematosus. Mycoses. 46:(3-4):2003;145-148
22. Decostere A., Hermans K., De Baere T., Pasmans F., Haesebrouck F. First report on Cryptococcus laurentii associated with feather loss in a glossy starling (Lamprotornis chalybaeus). Avian Pathol. 32:(3):2003;309-311
23. Ohira S., Isoda K., Hamanaka H., Takahashi K., Nishimoto K., Mizutani H. Case report. Phaeohyphomycosis caused by Phialophora verrucosa developed in a patient with non-HIV acquired immunodeficiency syndrome. Mycoses. 45:(1-2):2002;50-54
24. Walsh T.J., Grol A., Hiemenz J., Fleming R., Roilides E., Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 10:(Suppl 1):2004;48-66
25. Supparatpinyo K., Perriens J., Nelson K.E., Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. 339:1998;1739-1743
26. Supparatpinyo K., Khamwan C., Baosoung V., Nelson K., Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet. 344:1994;110-113
27. Collins L., Samore M., Roberts M., Luzzati R., Jenkins R., Lewis W., et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 170:1994;644-652
28. Supparatpinyo K., Nelson K., Merz W.G., Breslin B., Cooper C.J., Khamwan C., et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 37:1993;2407-2411
29. Sirisanthana T., Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis. 3:1998;48-53
30. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 17:2003;113-134
31. Arend S.M., Westendorp R., Kroon F.P., van't Wout J.W., Vandenbroucke J.P., van Es A., et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 22:1996;920-925
32. Kusne S., Dummer J., Singh N., Iwatsuki S., Makowka L., Esquivel C., et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine. 67:1988;132-143
33. Kusne S., Torre-Cisneros J., Manez R., Irish W., Martin M., Fung J., et al. Factors associated with invasive lung aspergillosis and significance of positive cultures after liver transplantation. J Infect Dis. 166:1992;1379-1383
34. Christianson J.C., Engber W., Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol. 41:(3):2003;177-188
35. Cornet M., Mallat H., Somme D., Guerot E., Kac G., Mainardi J.L., et al. Fulminant invasive pulmonary aspergillosis in immunocompetent patients - a two-case report. Clin Microbiol Infect. 9:(12):2003;1224-1227
36. Romani L. Immunity to fungal infections. Nat Rev Immunol. 4:(1):2004;1-23
37. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 3:(11):2003;685-702
38. Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 38:(3):2004;311-320
39. Alvarez-Lerma F., Nolla-Salas J., Leon C., Palomar M., Jorda R., Carrasco N., et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 29:(7):2003;1069-1076
40. Prabhu R.M., Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 10:(Suppl 1):2004;31-47
41. Hopkins M.A., Treloar D.M. Mucormycosis in diabetes. Am J Crit Care. 6:(5):1997;363-367
42. Schelenz S., Gransden W.R. Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period. Mycoses. 46:(9-10):2003;390-396
43. Dean D.A., Burchard K.W. Fungal infection in surgical patients. Am J Surg. 171:(3):1996;374-382
44. Latenser B.A. Fusarium infections in burn patients: a case report and review of the literature. J Burn Care Rehabil. 24:(5):2003;285-288
45. Becker W.K., Cioffi W.G. Jr., McManus A.T., Kim S.H., McManus W.F., Mason A.D., et al. Fungal burn wound infection. A 10-year experience. Arch Surg. 126:(1):1991;44-48
46. Pruitt B.A. Jr., McManus A.T., Kim S.H., Goodwin C.W. Burn wound infections: current status. World J Surg. 22:(2):1998;135-145
47. Dignani M.C., Anaissie E. Human fusariosis. Clin Microbiol Infect. 10:(Suppl 1):2004;67-75
48. Hiemenz J.W., Kennedy B., Kwon-Chung K. Invasive fusariosis associated with an injury with a stringray barb. J Med Vet Mycol. 28:1990;209-213
49. Wheeler M.S., McGinnis M., Schell W.A., Walker D.H. Fusarium infection in burned patients. Am J Clin Pathol. 75:1981;304-311
50. Ayliffe G.A. Role of the environment of the operating suite in surgical wound infection. Rev Infect Dis. 13:(Suppl 10):1991;S800-S804
51. Bisno A.L. Cutaneous infections: microbiologic and epidemiologic considerations. Am J Med. 76:(5A):1984;172-179
52. Queiroz-Telles F., McGinnis M.R., Salkin I., Graybill J.R. Subcutaneous mycoses. Infect Dis Clin North Am. 17:(1):2003;59-85. viii
53. Clarke D.E., Raffin T.A. Infectious complications of indwelling long-term central venous catheters. Chest. 97:(4):1990;966-972
54. Rotstein C., Brock L., Roberts R.S. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer patients. Infect Control Hosp Epidemiol. 16:(8):1995;451-458
55. Lundstrom T., Sobel J. Nosocomial candiduria: a review. Clin Infect Dis. 32:(11):2001;1602-1607
56. Perfect J.R., Casadevall A. Cryptococcosis. Infect Dis Clin North Am. 16:2002;837-874
57. Pappas P.G., Perfect J., Cloud G.A., Larsen R.A., Pankey G.A., Lancaster D.J., et al. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis. 33:2001;690-699
58. Schupbach C.W., WC, Briggaman R.A. Cutaneous manifestations of disseminated cryptococcosis. Arch Dermatol. 112:1976;1734-1744
59. van Elden L.J., Walenkamp A., Lipovsky M.M. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS. 14:2000;2787-2788
60. WHO declares failure to deliver AIDS medicines a global health emergency. Bull World Health Organ. 81:(10):2003;776
61. Rassool G.H. Global AIDS treatment emergency. J Adv Nurs. 45:(2):2004;223-224
62. Wheat L.J., Kauffman C.A. Histoplasmosis. Infect Dis Clin North Am. 17:(1):2003;1-19. vii.
63. Lin S.J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 32:2001;358-366
64. Singh N. The changing face of invasive aspergillosis in liver transplant recipients. Liver Transplant. 8:2002;1071-1072
65. Marr K.A., Patterson T., Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 16:2002;875-894
66. Husain S., Alexander B., Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 37:2003;221-229
67. Bartlett J.A., Hulette C. Central nervous system pneumocystosis in a patient with AIDS. Clin Infect Dis. 25:(1):1997;82-85
68. Marr K.A., Carter R., Cirppa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 34:2002;909-917
69. Wald A., Leisenring W., van Burik J., Bowden R. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 175:1997;1459-1466
70. Baddley J.W., Stroud T., Salzman D., Pappas P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 32:2001;1319-1324
71. Kontoyiannis D.P., Wessel V., Bodey G.P., Rolston K.V. Zygomycosis in the 1990s in a tertiary care cancer center. Clin Infect Dis. 30:2000;851-856
72. Nosari A., Oreste P., Montillo M., et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica. 85:2000;1068-1071
73. Hiestand P.C., Graber M., Hurtenbach U., Herrmann P.K., Cammisuli S., Richardson B.P., et al. The new cyclosporine derivative, SDZ IMM 125: in vitro and in vivo pharmacological effects. Transplant Proc. 19:1992;31-38
74. Ochiai T.A., Nakajima K., Nagatar M., Suzuki T., Asano T., Uematsu A.T., et al. Effect of a new immunosuppressive agent, FK506, on heterotropic cardiac allotransplantation in the rat. Transplant Proc. 19:1987;1284-1286
75. Singh N. Antifungal prophylaxis in organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 31:2000;545-553
76. Tollemar J., Ericzon B., Barkhold L., Anderson J., Ringden O., Groth C.G. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc. 22:1990;1826-1827
77. Briegel J., Forst H., Spill B., Haas A., Grabein B., Haller M., et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 14:1995;375-382
78. Castaldo P., Stratta R., Wood R.P., Markin R., Patil K., Shaefer M., et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 126:1991;149-156
79. Singh N., GT, Wagener M.M., Doyle H., Marino I.R. Invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppressive agent. Clin Infect Dis. 24:1997;179-184
80. Singh N., HS. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 22:2003;258-266
81. Benedetti E., Gruessner A., Troppmann C., Papalois B.E., Sutherland D.E.R., Dunn D.L., et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 183:1996;307-316
82. Evertt J.E., Wahoff D., Statz G.K.J., Gruessner A., Gruessner R.W.G., Gores P.F., et al. Characterization and impact of wound infection after pancreas transplantation. Arch Surg. 129:1994;1310-1317
83. Cisneros J.M., Munoz P., Torre-Cisneros J., Gurgui M., Rodriguez-Hernandez M.J., Aguado J.M., et al. Pneumonia after heart transplantation: a multi-institutional study. Clin Infect Dis. 27:1998;324-331
84. Kanj S.S., Welty-Wolf K., Madden J., Tapson V., Baz M.A., Davis D., et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine. 75:1996;142-156
85. Cahill B.C., Hibbs J., Savik K., Juni B.A., Dosland B.M. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 112:1997;1160-1164
86. Horvath J., Dummer S., Lloyd J., Walker B., Merrill W.H. Infection in the transplanted and native lung after single lung transplantation. Chest. 104:1993;681-685
87. Nunley D.R., Ohori N., Grgurich W.F., Iacono A.T., Williams P.A., Keenan R.J., et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 114:1998;1321-1329
88. Paradowski L. Saprophytic fungal infections and lung transplantation - revisited. J Heart Lung Transplant. 16:1997;524-531
89. Singh N., Arnow P., Bonham A., Dominguez E., Paterson D.L., Pankey G.A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation. 64:1997;716-720
90. Torre-Cisnero J., Lopez O., Kusne S., Martinez A.J., Starzl T.E. CNS aspergillosis in organ transplantation: a clinicopathologic study. J Neurol Neurosurg Psych. 56:1993;188-193
91. Jabbour N., Reyes J., Kusne S., Martin M., Fung J. Cryptococcal meningitis after liver transplantation. Transplantation. 61:1996;146-167
92. John G.T., Mathew M., Snehaltha E., Anandi V., Date A., Jacob C.K., et al. Cryptococcosis in renal allograft recipients. Transplantation. 58:1994;855-856
93. Husain S., Wagner M., Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 7:2001;1-7
94. Singh N., Chang F., Gayowski T., Marino I.R. Infections due to dematiaceous fungi in organ transplant recipients. Clin Infect Dis. 24:1997;369-374
95. Arikan S., Lozano-Chiu M., Paetznick V., Rex J. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrobial Agents Chemother. 45:2001;. 327-300
96. Lionakis M.S., Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet. 362:(9398):2003;1828-1838
97. Rangel-Guerra R.A., Martinez H.R., Saenz C., Bosques-Padilla F., Estrada-Bellmann I. Rhinocerebral and systemic mucormycosis. Clinical experience with 36 cases. J Neurol Sci. 143:(1-2):1996;19-30
98. Parfrey N. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine. 65:1986;113-123
99. Lee F.Y., Mossad S., Adal K.A. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 159:1999;1301-1309
100. Pisetsky D.S. Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med. 342:(11):2000;810-811
101. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 343:(22):2000;1594-1602
102. Braun J., de Keyser F., Brandt J., Mielants H., Sieper J., Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol. 13:(4):2001;245-249
103. Sandborn W.J., Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 5:(2):1999;119-133
104. Warris A., Bjorneklett A., Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 344:(14):2001;1099-1100
105. Myers A., Clark J., Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 346:(8):2002;623-626
106. Stringer J.R., Beard C.B., Miller R.F., Wakefield A.E. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 8:(9):2002;891-896
107. Stringer J.R. Pneumocystis. Int J Med Microbiol. 292:(5-6):2002;391-404
108. Armbruster C., Pokieser L., Hassl A. Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients. Comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase chain reaction. Acta Cytol. 39:(6):1995;1089-1093
109. Elwood L.J., Dobrzanski D., Feuerstein I.M., Solomon D. Pneumocystis carinii in pleural fluid. The cytologic appearance. Acta Cytol. 35:(6):1991;761-764
110. Shiota T. Simultaneous demonstration of cyst walls and intracystic bodies of Pneumocystis carinii in paraffin embedded lung sections using Gomori's methenamine silver nitrate and Giemsa stain. J Clin Pathol. 39:(11):1986;1269- 1271
111. Serraino D., Puro V., Boumis E., Angeletti C., Girardi E., Petrosillo N., et al. Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000. AIDS. 17:(14):2003;2109-2116
112. Aviles R., Boyce T.G., Thompson D.M. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc. 79:(2):2004;243-245
113. Clarke E., Glaser A.W., Picton S.V. Pneumocystis carinii pneumonia: a late presentation following treatment for stage IV neuroblastoma. Pediatr Hematol Oncol. 20:(6):2003;467-471
114. Sundar K., Rosado-Santos H., Reimer L., Murray K., Michael J. Unusual presentation of thoracic Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 32:(3):2001;498-501
115. Patel S.K., Philpott J.M., McPartlin D.W. An unusual case of Pneumocystis carinii presenting as an aural mass. J Laryngol Otol. 113:(6):1999;555-557
116. Kinchen K., Kinchen T.H., Inglesby T. Jr. Pneumocystis carinii infection of the small intestine. J Natl Med Assoc. 90:(10):1998;625-627
117. Ng V.L., Yajko D.M., Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 10:(3):1997;401-418
118. Kirsch C.M., Azzi R.L., Yenokida G.G., Jensen W.A. Analysis of induced sputum in the diagnosis of Pneumocystis carinii pneumonia. Am J Med Sci. 299:(6):1990;386-391
119. Roux P., Lavrard I., Poirot J.L., Chouaid C., Denis M., Olivier J.L., et al. Usefulness of PCR for detection of Pneumocystis carinii DNA. J Clin Microbiol. 32:(9):1994;2324-2326
120. Ortona E., Margutti P., Tamburrini E., Mencarini P., Visconti E., Zolfo M., et al. Detection of Pneumocystis carinii in respiratory specimens by PCR-solution hybridization enzyme-linked immunoassay. J Clin Microbiol. 35:(6):1997;1589-1591
121. Sing A., Trebesius K., Roggenkamp A., Russmann H., Tybus K., Pfaff F., et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol. 38:(4):2000;1461-1467
122. Matos O., Lundgren B., Caldeira L., Mansinho K., Aguiar P., Forte M., et al. Evaluation of a nested PCR for detection of Pneumocystis carinii in serum from immunocompromised patients. J Eukaryot Microbiol. 46:(5):1999;104S-105S
123. Helweg-Larsen J., Jensen J.S., Benfield T., Svendsen U.G., Lundgren J.D., Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 36:(7):1998;2068-2072
124. Weig M., Klinker H., Bogner B.H., Meier A., Gross U. Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups. J Clin Microbiol. 35:(6):1997;1445-1449
125. Groll A.H., Walsh T. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 7:(Suppl 2):2001;8-24
126. Perfect J.R., Shell W. The new fungal opportunists are coming. Clin Infect Dis. 22:(Suppl 2):1996;S112-S118
127. Anaissie E., Kantarjian H., Ro J., Hopfer R., Ralston K., Fainstein V., et al. The emerging role of Fusarium infection in patients with cancer. Medicine. 67:1988;77-83
128. Schwartz J. The diagnosis of deep mycosis by morphological methods. Hum Pathol. 13:1982;519-533
129. Groll A.H., Shah P., Mentzel C., Schneider M., Just-Nuebling G., Huebner K., et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 33:1996;23-32
130. Holzheimer R.G., Dralle H. Management of mycoses in surgical patients - review of the literature. Eur J Med Res. 7:(5):2002;200-226
131. Mousa H.A. Fungal infection of burn wounds in patients with open and occlusive treatment methods. East Mediterr Health J. 5:(2):1999;333-336
132. van Burik J.A., Colven R., Spach D.H. Cutaneous aspergillosis. J Clin Microbiol. 36:(11):1998;3115-3121
133. Rodgers G.L., Mortensen J., Fisher M.C., Lo A., Cresswell A., Long S.S. Predictors of infectious complications after burn injuries in children. Pediatr Infect Dis J. 19:(10):2000;990-995
134. Aguado J.M., Valle R., Arjona R., Ferreres J.C., Gutierrez J.A. Aortic bypass graft infection due to Aspergillus: report of a case and review. Clin Infect Dis. 14:(4):1992;916-921
135. Moore C.B., SN, Mosquera J., Slaven J., Denning D. Antifungal drug resistance in Aspergillus. J Infect. 41:2000;203-220
136. Tritz D., WG. Fatal disseminated infection with Aspergillus terreus in the immunocompromised patient. Clin Infect Dis. 16:1993;118-122
137. Sampathkumar P., PC. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 32:2001;1237-1240
138. Boutati E.I., Anaissie E. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a center and implications for management. Blood. 90:1997;999-1008
139. Krcmery V. Jr., Jesenska Z., Spanik S., Gyarfas J., Nogova J., Botek R., et al. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect. 36:1997;223-228
140. Guarro J., GJ. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis. 14:1995;741-754
141. Martino P., GR, Raccah R., Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 28:(Suppl 1):1994;7-15
142. Musa M.O., AEA, Halim M., et al. The spectrum of Fusarium infection in immunocompromised patients with hematological malignancies and in non-immunocompromised patients. Br J Hematol. 108:2000;544-548
143. Gamis A.S., GT, Giebink G.S., Ramsay N.K. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis. 13:1991;1077-1088
144. Heenequin C., Lavarde V., Poirot J.L., Rabodonirina M., Datry A., Aractingi S., et al. Invasive Fusarium infections: a retrospective survey of 31 cases. The Groupe d'Études des Mycoses Opportunistes (GEMO). J Med Vet Mycol. 33:1997;107-114
145. Nucci M., Anaissie A. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implication for diagnosis and management. Clin Infect Dis. 35:2002;909-920
146. Abramowsky C.R., Quinn D., Bradford W.D., Conant N.F. Systemic infection by fusarium in a burned child. The emergence of a saprophytic strain. J Pediatr. 84:1974;561-564
147. St-Germain G., Summerbell R. Fusarium. St-Germain G.S.R. Identifying filamentous fungi. 1996;122-123 Blackwell Science, Blemont (CA)
148. Anaissie E.J., Nelson P., Beremand M., Kontoyiannis D., Rinaldi M. Fusarium-caused hyalohyphomycosis: an overview. Curr Top Med Mycol. 4:1992;231-249
149. Anaissie E.J., Rinaldi M. Fusarium and the immunocompromised host: liaisons dangereuses [comment]. New York State J Med. 90:1990;586-587
150. Caux F., Aractingi S., Baurmann H., Reygagne P., Dombret H., Romand S., et al. Fusarium solani cutaneous infection in a neutropenic patient. Dermatology. 186:1993;232-235
151. Reuben A., Anaissie E., Nelson P.E., Hashem R., Legrand C., Ho D., et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother. 33:1989;1647-1649
152. Anaissie E.J., Hachem R., Legrand C., Legenne P., Nelson P., Bodey G. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis. 165:1992;1155-1157
153. Walsh T.J., Finberg R., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 340:1999;764-771
154. Walsh T.J., Hiemenz J., Seibel N., Perfect J., Horwith G., Lee L., et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 26:1998;1383-1396
155. Merz W., Karp J., Hoagland M., Jetta-Goheen M., Junkins J., et al. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis. 158:1998;1046-1055
156. Walsh T.J., Goodman J., Pappas P., Bekersky I., Buell D., Roden M., et al. Safety, tolerance, and pharmacokinetics of high dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: a maximum tolerated dose study. Antimicrob Agents Chemother. 45:2001;3487-3496
157. Goldblum D., Frueh B., Zimmerli S., Bohnke M. Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. Cornea. 19:2000;853-856
158. Wolff M.A., Ramphal R. Use of amphotericin B lipid complex for treatment of disseminated cutaneous Fusarium infection in a neutropenic patient. Clin Infect Dis. 20:1995;1568-1569
159. Viviani M.A., Cofrancesco E., Boschetti C., Tortorano A.M., Cortellaro M. Eradication of Fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses. 34:1991;255-256
160. Ellis M.E., Clink H., Younge D., Hainau B. Successful combined surgical and medical treatment of fusarium infection after bone marrow transplantation. Scand J Infect Dis. 26:1994;225-228
161. Cofrancesco E., Boschetti C., Viviani M.A., Bargiggia C., Tortorano A., Cortellaro M., et al. Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient. Haematologica. 77:1992;280-283
162. Reis A., Sundmacher R., Tintelnot K., Agostini H., Jensen H.E., Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 84:2000;932-933
163. Espinel-Ingroff A. Comparison of in-vitro activities of new triazole SCH 56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956
164. Travis L.B., Roberts G., Wilson W.R. Clinical significance of Pseudallescheria boydii: a review of 10 years' experience. Mayo Clin Proc. 60:1985;531-537
165. Kershaw P., Freeman R., Templeton D., DeGirolami P., DeGirolami U., Tarsy D., et al. Pseudallescheria boydii infection of the central nervous system. Arch Neurol. 47:1990;468-472
166. Patterson T.F., Andriole V., Zervos M.J., Therasse D., Kauffman C. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community acquired infection. Mycosis. 33:1990;297-302
167. Berenguer J., Diaz-Mediavilla J., Urra D., Munoz P. Central nervous system infection caused by Pseudallescheria boydii: case report and review. Rev Infect Dis. 60:1990;531-537
168. Tadros T.S., Workowski K., Siegel R.J., Hunter S. Pathology of hyalophyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Human Pathol. 29:1998;1266-1272
169. Lopez F.A., Crowley R., Wastila L., Valantine H., Remington J. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. J Heart Lung Transplant. 17:1998;321-324
170. Fincher R.M., Fisher J., Lovell R.D., Newman C., Espinel-Ingroff A., shadomy H. Infection due to the fungus Acremonium (Cephalosporium). Medicine. 70:1991;398-409
171. Roilides E.S., Bibashi E., Acritidou E., Trahana M., Gompakis N., Karpouzas J., et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J. 14:1995;548-550
172. Kouvousis N., Lazaros G., Christoforatou E., Deftereos S., Petropoulou-Milona D., Lelekis M., et al. Pacemaker pocket infection due to Acremonium species. Pacing Clin Electrophysiol. 25:2002;378-379
173. Miro O., Fernando J., Lecha V., Campistol J.M. Subcutaneous abscesses caused by Acremonium falciforme in a kidney transplant recipient. Med Clin (Barc). 102:1994;316
174. Strabelli T.M., Uip D., Amato N., Bocchi E., Higuchi Stolf N., et al. Acremonium infection after heart transplant. Rev Soc Bras Med Trop. 23:1990;233
175. Hebrecht R., Letscher-Bru V., Fohrer C., Campos F., Natarajan-Ame S., Zamfir A., et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis. 21:2002;814-817
176. Guarro J., Gams W., Pujol I., Gene J. Acremonium species: new emerging fungal opportunities: in vitro antifungal susceptibilities and review. Clin Infect Dis. 25:1997;1222-1229
177. Fung-Tonc J.C., Huczko E., Minassian B., Bonner D.P. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother. 42:1998;313-318
178. Schell W.A., Perfect J. Fatal disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol. 34:1996;1333-1336
179. Blackwell V., Ahmed K., O'Docherty C., Hay R.J. Cutaneous hyalophyphomycosis caused by Paecilomyces lilacinus in a renal transplant patient. Br J Dermatol. 143:2000;873-875
180. Castro L.G., Salebian A., Sotto M.N. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections. J Med Vet Mycol. 28:1990;15-26
181. Hilmarsdottir I., Thorsteinsson S., Asmundsson P., Bodvarsson M., Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis. 32:2000;331-332
182. Das A., MacLaughlin E., Ross L.A., Monforte H., Horn M., Lam G., et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant. 4:2000;328-332
183. Lee J., Yew W., Chiu C.S., Wong P., Wong C., Wang E. Delayed sternotomy wound infection due to Paecilomyces variotii in a lung transplant recipient. J Heart Lung Transplant. 21:2002;1131-1134
184. Chan-Tack K.M., Thio C., Miller N.S., Karp C., Ho C., Merz W. Paecilomyces lilacinus fungemia in adult marrow transplant recipient. Med Mycol. 37:1999;57-60
185. Orth B., Frei R., Itin P.H., Rinaldi M., Speck B., Gratwohl A., et al. Outbreak of invasive mycosis caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med. 125:1996;799-806
186. Shing M.M., Ip M., Li C.K., Chik K., Yuen P. Paecilomyces variotii
187. Tan T.Q., Ogden A., Tillman J., Demmler G., Rinaldi M. Paecilomyces lilacinus catheter-related fungemia in immunocompromised pediatric patient. J Clin Microbiol. 30:1992;2479-2483
188. Naiad J., Singh S. Hyalophyphomycosis caused by Paecilomyces variotii: a case report, animal pathogenicity and in vitro sensitivity. Antoine Van Leeuwenhoek. 62:1992;225-230
189. Williamson P.R., Kwon-Chung K., Gallin J.I. Successful treatment of Paecilomyces variotii in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis. 14:1992;1023-1026
190. Pettit T.H., Olson R., Foos R.Y., Martin W. Fungal endophthalmitis following intraocular lens implantation. A surgical epidemic. Arch Ophthalmol. 98:1980;1025-1039
191. Wildfeurer A., Seidl H., Paule I., Haberreiter A. In vitro activity of voriconazole against yeasts, moulds, and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittelforschung. 47:1997;1257-1263
192. Aguilar C., Sala J., Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother. 42:1998;1601-1604
193. Sellier P., Monsuez J., Lacroix C., Feray C., Evans J., Minozzi C., et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis. 30:2000;820-823
194. Schmidt J.H., Howard R.J., Chen J.L., Pierson K.K. First culture-proven gastrointestinal entermophthoromycosis in the United States: a case report and review of the literature. Mycopathologia. 95:(2):1986;101-104
195. Pasha T.M., Leighton J.A., Smilack J.D., Heppell J., Colby T.V., Kaufman L. Basidiobolomycosis: an unusual fungal infection mimicking inflammatory bowel disease. Gastroenterology. 112:(1):1997;250-254
196. Lyon G.M., Smilack J.D., Komatsu K.K., Pasha T.M., Leighton J.A., Guarner J., et al. Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. Clin Infect Dis. 32:(10):2001;1448-1455
197. Frater J.L., Hall G.S., Procop G.W. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 125:(3):2001;375-378
198. Zhang Z., Correa H., Begue R.E. Tuberculosis and treatment with infliximab. N Engl J Med. 346:(8):2002;623-626
199. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 46:(10):2002;2565-2570
200. Wood K.L., Hage C.A., Knox K.S., Kleiman M.B., Sannuti A., Day R.B., et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 167:(9):2003;1279-1282
201. Nakelchik M., Mangino J.E. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 112:(1):2002;78
202. Waite R.T., Woods G.L. Evaluation of BACTEC MYCO/F lytic medium for recovery of mycobacteria and fungi from blood. J Clin Microbiol. 36:(5):1998;1176-1179
203. Martagon-Villamil J., Shrestha N., Sholtis M., Isada C.M., Hall G.S., Bryne T., et al. Identification of Histoplasma capsulatum from culture extracts by real-time PCR. J Clin Microbiol. 41:(3):2003;1295-1298
204. Brandt M.E., Warnock D.W. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother. 15:(Suppl 2):2003;36-47
205. Kantarcioglu A.S., de Hoog G.S. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses. 47:(1-2):2004;4-13
206. Revankar S.G., Sutton D., Rinaldi M.G. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis. 38:2004;206-216
207. Groll A., Walsh T. Pharmacology of antifungal compounds. Adv Pharmacol. 44:1998;343-350
208. McGinnis M.R., Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 36:1998;2353-2355
209. McGinnis M.R., Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol. 36:1998;243-246
210. Sharkey P.K., Graybill J., Rinaldi M.G., Stevens D., Tucker R., Peterie J., et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol. 23:1990;577-586
211. McDonald L.C., Weinstein M.P., Fune J., Mirrett S., Reimer L.G., Reller L.B. Controlled comparison of BacT/ALERT FAN aerobic medium and BACTEC fungal blood culture medium for detection of fungemia. J Clin Microbiol. 39:(2):2001;622-624
212. Eng R., Bishburg E., Smith S.M. Bacteremia and fungemia in patients with the acquired immune deficiency syndrome. Am J Clin Pathol. 86:1986;105-107
213. Chuck S.L., Sande M. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 321:1989;794-799
214. Clark R.A., Greer D., Atkinson W., Valainis G.T., Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with acquired immunodeficiency virus. Rev Infect Dis. 12:1990;768-777
215. Currie B.P., Casadevall A. Estimation of the prevalence of cryptococcal infection among HIV-infected individuals in New York City. Clin Infect Dis. 19:1990;1029-1033
216. Sorvillo F., Beall G., Turner P.A. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS. 11:1997;673-679
217. Friedman G. The rarity of cryptococcosis in Northern California: the 10-year experience of a large defined population. Am J Epidemiol. 117:1983;230-234
218. Kaufman L., Blumer S. Proceedings of the Fourth International Conference on the Mycoses. Pan-American Health Organization. 356:1977;176-182
219. Hajjman A., Copnn L., Stephens D.S. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis. 179:1999;449-454
220. Thomas C.J., Lee J., Conn L.A. Surveillance of cryptococcosis in Alabama, 1992-1993. Ann Epidemiol. 8:1998;212-216
221. Kovacs J.A., Kovacs A., Polis M., Wright W.C., Gill V.J., Tuazon C.U., et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 103:1985;533-538
222. Zuger A., Louie E., Holzman R.S., Simberkoff M.S., Rahal J.J. Cryptococcal disease in patients with acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med. 104:1986;234-240
223. Zimmerman L.E., Rappaport H. Occurrence of cryptococcosis in patients with malignant disease of reticuloendothelial system. Am J Clin Pathol. 24:1954;1050
224. Kaplan M.H., Rosen P., Armstrong D. Cryptococcus in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer. 39:1977;2265-2274
225. Hutter R., Collins H. The occurrence of opportunistic fungus infections in a cancer hospital. Lab Invest. 1:1962;1035-1045
226. Kontoyiannis D.P., Peitsch W., Reddy B.T. Cryptococcosis in patients with cancer. Clin Infect Dis. 32:2001;145-150
227. Beyt B.E., Waltman S. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med. 298:1978;825-826
228. Casadevall A., Perfect J. Cryptococcus neoformans. 1998;ASM Press, Washington, DC
229. Salyer W.R., Salyer D., Baker R.D. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis. 130:1974;74-77
230. Haugen R.K., Baker R. The pulmonary lesions in cryptococcosis with special reference to subpleural nodule. J Clin Pathol. 24:1954;1381
231. Baker R. The primary pulmonary lymph node complex of cryptococcosis. Am J Clin Pathol. 65:1976;83-92
232. Fessel W. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med. 328:1993;1354-1355
233. Nosanchuk J.D., Shoham S., Fries B.C. Evidence for zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 132:2000;205-208
234. Lyman C.A., Devi S., Nathanson J., Frasch C., Pizzo P., Walsh T. Detection and quantification of the glucuronoxylomannan-like polysaccharide antigen from clinical and non-clinical isolates of Trichosporon beigelii: implications for pathogenicity. J Clin Microbiol. 33:1994;126-130
235. McManus E.J., Jones J. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol. 21:1985;681
236. Melcher G.A., Reed K., Rinaldi M.G., Lee J., Pizzo P., Walsh T. Demonstration of a cell wall antigen cross reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol. 29:1991;192-196
237. Procop G.W., Cockerill F.R. III, Vetter E.A., Harmsen W.S., Hughes J.G., Roberts G.D. Performance of five agar media for recovery of fungi from isolator blood cultures. J Clin Microbiol. 38:(10):2000;3827-3829
238. Gueho E., Smith M., de Hoog G.S., Billon-Grand G., Christen R., Batenburg-van der Vegte W.H. Contributions to a revision of the genus Trichosporon. Antoine Van Leeuwenhoek. 61:1992;289-316
239. Gueho E., Faergemann J., Lyman C., Anasissie E.J. Malassezia and Trichosporon: two emerging pathogenic basidiomycoetous yeast-like fungi. J Med Vet Mycol. 32:(Suppl 1):1994;367-378
240. Lee J.W., Melcher G., Rinaldi M.G., Andrews J., Pizzo P.A., Walsh T.J. Patterns of morphologic variation among isolates of Trichosporon beigelii. J Clin Microbiol. 28:1990;2823-2827
241. Walsh T.J., Melcher G., Lee J.W., Pizzo P.A. Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis, and treatment. Curr Top Med Mycol. 5:1993;79-113
242. Kemker B.J., Lehmann P., Lee J.W., Walsh T.J. Distinction of deep vs. superficial clinical and nonclinical isolates of Trichosporon beigelii by isoenzymes and restriction fragment length polymorphisms of rDNA generated by the polymerase chain reaction. J Clin Microbiol. 29:1991;1677-1683
243. Sugita T., Nichikawa A., Shinoda T. Reclassification of Trichosporon cutaneum by DNA relatedness by using the spectrophotometric method and chemiluminometric method. J Gen Appl Microbiol. 40:1994;397-408
244. Walsh T. Trichosporonosis. Infect Dis Clin North Am. 3:1989;43-52
245. Walsh T.J., Newman K., Moody M., Wharton R., Wade J. Trichosporonosis in patients with neoplastic disease. Medicine. 65:1986;268-279
246. Hoy J., Hsu K., Rolston K., Hopfer R., Luna M. Trichosporon beigelii infection: a review. Rev Infect Dis. 8:1986;959-967
247. Herbrecht R., Koening H., Waller K. Trichosporon infections: clinical manifestations and treatment. J Mycol Med. 3:1993;129-136
248. Martino P., Venditti M., Micozzi A., Morace G., Polonelli L., Mantovani M., et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemic patients. Rev Infect Dis. 12:1990;570-582
249. Sanz M.A., Lopez F., Martinez M.L., Sanz G., Martinez J., Martin G., et al. Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukemia. Report of three cases. Supportive Care Cancer. 4:1996;291-293
250. Ortiz A.M., Sanz-Rodriguez C., Culebras J., Buendia B., Gonzalez-Ivaro I., Ocon E., et al. Multiple spondylodiscitis caused by Blastoschizomyces capitatus in an allogeneic bone marrow transplantation recipient. J Rheumatol. 25:1998;2276-2278
251. Perez-Sanchez I., Aguita J., Martin-Rabadan P., Munoz P., Serrano D., Escudero A., et al. Blastoschizomyces capitatus in acute leukemia patients. Leukemia Lymphoma. 39:2000;209-212
252. D'Antonio D., Mazzoni A., Iacone A., Violante B., Capuani M., Schioppa F., et al. Emergence of fluconazole resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol. 34:1996;753-755
253. Hall G, Hall L, Joyce M, Lodge B, Procop G, et al. Multicenter evaluation of Candida albicans PNA FISH probe in blood cultures that contained yeast. Presented at the ASM General Meeting; May 18, 2003.